Short-term outcome of radiofrequency ablation combined with endostar in the treatment of non-small cell lung cancer: A non-randomized controlled trial_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

 LIU Baodong , HU Mu , LIU Lei , QIAN Kun , LI Yuanbo

Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing, 100053, P.R.China;

Corresponding?author：

LIU Baodong, Email: xwliubaodong@aliyun.com

Keywords：

Radiofrequency ablation; recombinant human endostatin (endostar); non-small cell lung cancer

DOI：

10.7507/1007-4848.201708053

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To study the short-term outcome and safety of radiofrequency ablation (RFA) combined with recombinant human endostatin (endostar) for non-small cell lung cancer (NSCLC) patients. Methods Between December 2013 and December 2014, 80 consecutive patients (50 males, 30 females) with biopsy-proved NSCLC were divided into two groups: a RFA combined treatment group (RFA combined with endostar, 60 patients, 38 males, 22 females, mean age at 67.77±10.43 years) and a RFA alone group (20 patients, 12 males, 8 females, mean age at 67.35±9.82 years). The RFA combined treatment group was divided into three groups according to vascular normalization window of endostar and 20 patients in each group: a combined treatment group 1 (transfusion of endostar after RFA), a combined treatment group 2 (transfusion of endostar for 1 to 3 d before RFA) and a combined treatment group 3 (transfusion of endostar for 4 to 7 d before RFA). The CT scan of the chest was followed up after the treatment, local recurrence and safety was observed. Results There was a statistical difference in local recurrence time among groups (χ² = 11.05, P = 0.011). The effect of the combined treatment group is better than that of the radiofrequency ablation therapy alone group. And in the recombinant human endostatin of tumor vascular normalization time best combination therapy was observed in the near future effect compared with the radiofrequency ablation therapy alone. In this study common complications were associated with radiofrequency ablation. No recombinant human endostatin related complication was found. There was no satistical difference in safety between the combined treatment group and the radiofrequency ablation therapy group (χ²= 0.889, P > 0.05). Conclusion RFA combined with endostar is safe and effective for non-small cell lung cancer.

Citation： LIU Baodong, HU Mu, LIU Lei, QIAN Kun, LI Yuanbo. Short-term outcome of radiofrequency ablation combined with endostar in the treatment of non-small cell lung cancer: A non-randomized controlled trial. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2018, 25(6): 477-481. doi: 10.7507/1007-4848.201708053 Copy

1.	Hiraki T, Gobara H, Mimura H, et al. Percutaneous radiofrequency ablation of clinical stage I non-small cell lung cancer. J Thorac Cardiovasc Surg, 2011, 142(1): 24-30.
2.	Beland MD, Wasser EJ, Mayo-Smith WW, et al. Primary non-small cell lung cancer: review of frequency, location, and time of recurrence after radiofrequency ablation. Radiology, 2010, 254(1): 301-307.
3.	Lanuti M, Sharma A, Willers H, et al. Radiofrequency ablation for stage I non-small cell lung cancer: management of locoregional recurrence. Ann Thorac Surg, 2012, 93(3): 921-927.
4.	Steinke K, Haghighi KS, Wulf S, et al. Effect of vessel diameter on the creation of ovine lung radiofrequency lesions in vivo: preliminary results. J Surg Res, 2005, 124(1): 85-91.
5.	Goldberg SN, Gazelle GS, Compton CC, et al. Radiofrequency tissue ablation in the rabbit lung: efficacy and complications. Acad Radiol, 1995, 2(9): 776-784.
6.	劉寶東, 胡牧, 劉磊, 等. 重組人血管內皮抑素在非小細胞肺癌患者腫瘤血管正常化時間窗研究. 中國醫學前沿雜志 (電子版), 2017, 9(3): 8-12.
7.	潘杰, 陳紹輝, 盧欣, 等. 全麻下 CT 引導下經皮穿刺射頻消融治療肝內特殊部位的惡性腫瘤. 介入放射學雜志, 2010, 19(6): 478-481.
8.	劉寶東, 支修益. 影像引導下熱消融治療肺部腫瘤的局部療效評價. 中國醫學前沿雜志 (電子版), 2015, 7(2): 11-14.
9.	Goldberg SN, Gazelle GS, Mueller PR. Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. AJR Am J Roentgenol, 2000, 174(2): 323-331.
10.	Huang G, Chen L. Discrepancies between antiangiogenic and antitumor effects of recombinant human endostatin. Cancer Biother Radiopharm, 2009, 24(5): 589-596.
11.	黃桂, 陳龍邦. 重組人內皮抑素對荷人肺腺癌裸鼠腫瘤微環境的調節作用. 癌癥進展, 2009, 7(5): 495-499.
12.	Huang G, Chen L. Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res Clin Oncol, 2010, 136(8): 1201-1211.
13.	Peng F, Xu Z, Wang J, et al. Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models. PLoS One, 2012, 7(4): e34646.
14.	Jiang XD, Dai P, Qiao Y, et al. Clinical study on the recombinant human endostatin regarding improving the blood perfusion and hypoxia of non-small-cell lung cancer. Clin Transl Oncol, 2012, 14(6): 437-443.
15.	Jiang XD, Dai P, Wu J, et al. Effect of recombinant human endostatin on radiosensitivity in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 2012, 83(4): 1272-1277.
16.	Li N, Zheng D, Wei X, et al. Effects of recombinant human endostatin and its synergy with cisplatin on circulating endothelial cells and tumor vascular normalization in A549 xenograft murine model. J Cancer Res Clin Oncol, 2012, 138(7): 1131-1144.
17.	王澤新, 李艷彥, 朱偉良, 等.恩度聯合微波消融治療鼠肝癌移植瘤研究. 海南醫學, 2012, 23(3): 27-29.
18.	溫居一, 段蘊鈾, 聶青, 等. 氬氦刀冷凍消融序貫重組人血管內皮抑制素治療晚期復治非小細胞肺癌的臨床研究. 武警醫學, 2012, 23(2): 120-123.
19.	Ma CH, Jiang R, Li JD, et al. Experimental study of Endostar injection concomitant with cryoablation on lung adenocarcinoma A549 xenografts. Asian Pac J Cancer Prev, 2014, 14(11): 6697-6701.

1. Hiraki T, Gobara H, Mimura H, et al. Percutaneous radiofrequency ablation of clinical stage I non-small cell lung cancer. J Thorac Cardiovasc Surg, 2011, 142(1): 24-30.
2. Beland MD, Wasser EJ, Mayo-Smith WW, et al. Primary non-small cell lung cancer: review of frequency, location, and time of recurrence after radiofrequency ablation. Radiology, 2010, 254(1): 301-307.
3. Lanuti M, Sharma A, Willers H, et al. Radiofrequency ablation for stage I non-small cell lung cancer: management of locoregional recurrence. Ann Thorac Surg, 2012, 93(3): 921-927.
4. Steinke K, Haghighi KS, Wulf S, et al. Effect of vessel diameter on the creation of ovine lung radiofrequency lesions in vivo: preliminary results. J Surg Res, 2005, 124(1): 85-91.
5. Goldberg SN, Gazelle GS, Compton CC, et al. Radiofrequency tissue ablation in the rabbit lung: efficacy and complications. Acad Radiol, 1995, 2(9): 776-784.
6. 劉寶東, 胡牧, 劉磊, 等. 重組人血管內皮抑素在非小細胞肺癌患者腫瘤血管正常化時間窗研究. 中國醫學前沿雜志 (電子版), 2017, 9(3): 8-12.
7. 潘杰, 陳紹輝, 盧欣, 等. 全麻下 CT 引導下經皮穿刺射頻消融治療肝內特殊部位的惡性腫瘤. 介入放射學雜志, 2010, 19(6): 478-481.
8. 劉寶東, 支修益. 影像引導下熱消融治療肺部腫瘤的局部療效評價. 中國醫學前沿雜志 (電子版), 2015, 7(2): 11-14.
9. Goldberg SN, Gazelle GS, Mueller PR. Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. AJR Am J Roentgenol, 2000, 174(2): 323-331.
10. Huang G, Chen L. Discrepancies between antiangiogenic and antitumor effects of recombinant human endostatin. Cancer Biother Radiopharm, 2009, 24(5): 589-596.
11. 黃桂, 陳龍邦. 重組人內皮抑素對荷人肺腺癌裸鼠腫瘤微環境的調節作用. 癌癥進展, 2009, 7(5): 495-499.
12. Huang G, Chen L. Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res Clin Oncol, 2010, 136(8): 1201-1211.
13. Peng F, Xu Z, Wang J, et al. Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models. PLoS One, 2012, 7(4): e34646.
14. Jiang XD, Dai P, Qiao Y, et al. Clinical study on the recombinant human endostatin regarding improving the blood perfusion and hypoxia of non-small-cell lung cancer. Clin Transl Oncol, 2012, 14(6): 437-443.
15. Jiang XD, Dai P, Wu J, et al. Effect of recombinant human endostatin on radiosensitivity in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 2012, 83(4): 1272-1277.
16. Li N, Zheng D, Wei X, et al. Effects of recombinant human endostatin and its synergy with cisplatin on circulating endothelial cells and tumor vascular normalization in A549 xenograft murine model. J Cancer Res Clin Oncol, 2012, 138(7): 1131-1144.
17. 王澤新, 李艷彥, 朱偉良, 等.恩度聯合微波消融治療鼠肝癌移植瘤研究. 海南醫學, 2012, 23(3): 27-29.
18. 溫居一, 段蘊鈾, 聶青, 等. 氬氦刀冷凍消融序貫重組人血管內皮抑制素治療晚期復治非小細胞肺癌的臨床研究. 武警醫學, 2012, 23(2): 120-123.
19. Ma CH, Jiang R, Li JD, et al. Experimental study of Endostar injection concomitant with cryoablation on lung adenocarcinoma A549 xenografts. Asian Pac J Cancer Prev, 2014, 14(11): 6697-6701.

Previous Article
Verification, comparison and melioration of different prediction models for solitary pulmonary nodule
Next Article
Impact of climate change on aortic dissection onset

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Short-term outcome of radiofrequency ablation combined with endostar in the treatment of non-small cell lung cancer: A non-randomized controlled trial

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content